Kornimate/medical-research-clean huggingface dataset:
liver stiffness measurement (lsm) in predicting progress of liver fibrosis after tace for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Liver Failure

Summary: objective: to evaluate the efficacy of preoperative liver stiffness measurement(lsm) by fibroscan in predicting the progress of liver fibrosis and prognosis after transcatheter arterial chemoembolization (tace) in hepatocellular carcinoma (hcc). background: progress of liver fibrosis and liver failure and related poor prognosis after tace which are not completely predictable by current method including child-pugh classification. lsm is used to calculate the degree of liver fibrosis and is affected by several liver injury, e.g. elevated alanine aminotransferase（alt）, aspartate transaminase(ast) and bilirubin et al. the investigators assume that lsm could be use to predict progress of liver fibrosis and adverse effects after tace in hcc. methods: at least 200 patients will be recruited in this prospective observational study with preoperative lsm, demographic, laboratory, radiological and other treatment-related factors. participants will be followed up till death or to the end of study no matter the liver failure occurs or not. data will be analyzed to build a mathematical predicting model. research hypothesis：tace is related to progress of liver fibrosis and a mathematical model with lsm is able to predict the risk of liver failure and prognosis in hcc.


Eligibility criteria:
inclusion criteria: * age：18-80 * hcc diagnosed by pathologist or physician according to guidelines * chronic hepatitis b (chb) background * receive at least 1 tace * volunteer to join the research exclusion criteria: * massive lesion with insufficient liver left for lsm examination * associated with other liver diseases: chronic hepatitis c(chc),autoimmune hepatitis(aih),wilson's disease. * severe obesity(bmi\>28) * pregnancy * other inappropriate situation defined by investigators.
longitudinal study of covid-19 infection among hcw in a french university hospital

Conditions: Sars-CoV2

Summary: the aim of the study is to determine the incidence o of sars-cov2 infection among health care workers highly exposed to covid 19 during 10 weeks et to analyze the determinants of their occupational and environmental exposure. every 14 days, we performed sars-cov2 rt- pcr, serological testing and clinical questionnaire among a cohort of 100 hcw with a high degree of exposure to covid19 infection. information about occupational exposure as the workplace, the activity of care, the characteristics of patient infected are captured, as well as environmental or personal exposure. the results will support the design of a new care organization and will define new ways of protection for patients (covid or not covid 19) and prevention for hcw.


Eligibility criteria:
inclusion criteria: - health care workers with covid high exposure during the care activities exclusion criteria: * heath care worker with sars-cov2 infection ( rt-pcr +) or sars-cov2 immunity in serological testing * hcw off work * subjects on leave

Keywords: incidence health care workers occupational exposure environmental exposure serological testing rt-pcr
low-dose cyclophosphamide and outpatient iv interleukin-2 in metastatic melanoma

Conditions: Metastatic Melanoma

Summary: the purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient il2.

to determine the response rate, median duration of response and median survival of patients treated with this low-dose cyclophosphamide + moderate dose bolus interleukin-2 schedule.

Eligibility criteria:
inclusion criteria: 1. patients must have a histologic diagnosis of metastatic melanoma. patients may have received prior systemic therapy or may be previously untreated. 2. patients must have measurable disease on physical exam or radiologic studies. 3. ecog performance status of 0 or 1 and estimated survival of at least 3 months. 4. white blood count of \> 3500/mm3, platelet count \> 100,000/mm3, hemoglobin \> 9.0 gm/dl; bilirubin, alt, ast \< 3 x upper limit of normal; serum creatinine \< 2.0 mg/dl. 5. patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. patients with a positive stress test would be excluded from this trial. 6. patients with elevated temperatures \> 100.5 f must have sources of occult infection excluded. 7. patients must be felt to have recovered from effects of prior therapy, such as \> 2 weeks after prior chemotherapy. 8. women of childbearing potential must have a negative pregnancy test and adequate precautions to prevent pregnancy during treatment must be taken. 9. patient consent must be obtained prior to entrance onto study. exclusion criteria: * 1. medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate. 2. autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy. 3. prior history of psychiatric disorder which could be exacerbated by interleukin-2. 4. lactation or pregnancy. 5. evidence of significant cardiovascular disease including history of recent (\< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional pvc's, angina, positive low-level stress test, or cerebrovascular accident. 6. current untreated brain metastasis.
randomized trial evaluating performance of the trevo retriever versus the merci retriever in acute ischemic stroke

Conditions: Ischemic Stroke

Summary: to determine if the trevo retriever is as good or better than the merci retriever in restoring blood flow to the brain of a patient experiencing an acute ischemic stroke in a large vessel.

the trevo 2 protocol was designed to assess the safety and effectiveness of the trevo retriever device and determine if it is substantially equivalent to the predicate merci retriever. the trial utilized a primary effectiveness endpoint of revascularization and a composite primary safety endpoint that included procedure-related serious adverse events occurring within 24 hours of the procedure. subjects who presented to enrolling centers with large ischemic strokes were screened for eligibility in the study. if a subject met eligibility criteria, then informed consent was obtained prior to commencing the angiogram. if all inclusion/exclusion criteria were confirmed, including the angiographic criteria, then the subject was randomized.the primary effectiveness endpoint was successful revascularization of the target occlusion, using the tici score. success was determined by the central core lab.the primary safety endpoint is a composite endpoint, described in the protocol as the "incidence of procedure-related serious adverse events (prsaes) through 24 hours post procedure (-6/+12 hours) defined as: vascular perforation or intramural arterial dissection, symptomatic ich, embolization to a previously uninvolved territory, access site complication requiring surgical repair or blood transfusion, intra-procedural mortality, device failure (in vivo breakage), or any other complications judged by the clinical events committee (cec) to be related to the procedure."

Eligibility criteria:
key inclusion criteria: * patient presenting with clinical signs and symptoms consistent with a diagnosis of acute ischemic stroke, and: * patient has failed iv t-pa therapy or * patient is contraindicated for iv t-pa administration * nihss 8 \< nihss \< 29 * anticipated life expectancy of at least 6 months * no significant pre-stroke disability (mrs \< 1) * written informed consent to participate given by patient or legal representative * angiographic confirmation of a persistent large vessel occlusion in the internal carotid, middle cerebral (m1 and/or m2 segments), basilar and/or vertebral arteries * treatable within 8 hours of symptom onset, defined as the first pass being made with the assigned study device key exclusion criteria: * abnormal blood pressure and/or blood coagulation lab values * pregnancy * patient participating in another investigational drug or device study * more than 1/3 of mca or equivalent in non-mca territory * baseline evidence of significant mass effect with midline shift, or hemorrhage, or intracranial tumor * bilateral stroke

Keywords: ischemia stroke ischemic stroke mechanical thrombectomy brain brain clot cerebrovascular disease recanalization revascularization
transcranial galvanic stimulation after stroke

Conditions: Stroke

Summary: transcranial galvanic stimulation (tdcs) seems to promote motor recovery after stroke by stimulating (anodal) or inhibiting (cathodal) neural circuits in the brain. in the treatment of severe arm paresis after stroke, robot-assisted arm training (at) proved to be effective, but nevertheless only a few patients could use their affected hand functionally in daily life after robot training. therefore the present study intends to combine both approaches, tdcs + at, applied at the same time every day for six weeks. the study has three treatment arms, two groups will receive the tdcs, either anodal of the lesioned or cathodal of the non-lesioned hemisphere. the anodal stimulation is expected to facilitate the activity of the arm motor area of the lesioned side directly, while the cathodal stimulation of the non-lesioned hemisphere is expected to facilitate the lesioned side indirectly by decreasing inhibitory inputs. the third group will receive a sham-stimulation. all patients will work with the at simultaneously to the tdcs, respectively sham-tdcs.


Eligibility criteria:
inclusion criteria: * subacute stroke * stroke interval 3 to 8 weeks * severe upper limb paresis * fugl-meyer \< 18 exclusion criteria: * history of epilepsy * antiepileptic, neuroleptic medication * metal implants

Keywords: hemiparesis rehabilitation upper limb rehabilitation arm therapy
kinetics of the finasteride prostate induced apoptosis

Conditions: Benign Prostatic Hyperplasia

Summary: the aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (bph). five sets of patients who need a surgical procedure because of low tract urinary symptoms are randomly attributed to one of five sets of treatment: 0, 7, 14, 21 or 28 days of finasteride treatment before the day of the procedure. prostate histological fragments are conditioned for molecular and histologic studies.


Eligibility criteria:
inclusion criteria: * patients with low tract urinary symptoms needing a surgical procedure * no previous treatment with finasteride * no androgen deficiency; no prostate cancer suspected.

Keywords: prostate apoptosis finasteride kinetics
osteoporosis disease management demonstration project (0000-040)

Conditions: Osteoporosis

Summary: the purpose of the study is to evaluate the impact disease management interventions in treatment compliance among post-fracture and osteoporosis patients.


Eligibility criteria:
inclusion criteria: * members of of the kaiser permanente health plan who have fractured a bone. exclusion criteria: * individuals who are not members of the kaiser permanente health plan.
efficacy of fluocinonide cream 0.1% (vanos(r)) in reducing itch in subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (vanos®) in the treatment of atopic dermatitis (ad).

the purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (vanos®) in the treatment of atopic dermatitis (ad). our hypothesis is that subjects will have a reduction in investigator's global assessment scores at day 7 and day 14 compared to baseline. secondary objectives include the use of actigraphy monitoring to determine the ability of vanos® cream to reduce itch, and thus nocturnal scratching, in ad. our hypothesis is that subjects will have a reduction in nocturnal scratching activity, as measured by actigraphy movement count per hour, at day 7 and day 14 compared to baseline. other secondary outcome measures include eczema area and severity index (easi) score, body surface area involvement and visual analog scale for itch. the investigators hypothesize that each of these measures will be improved at day 7 and day 14 compared to baseline.

Eligibility criteria:
inclusion criteria: * male or female with mild to severe atopic dermatitis, 12 years of age or older, that agree to participate and provide written consent (parent permission and assent if applicable). * have an investigator global assessment of mild to severe atopic dermatitis (iga rating of 2 through 4 in the investigator global assessment). * visual analog scale of itch score at baseline must be greater than or equal to 50 on a 100-point scale. * percentage of overall body surface area of involvement (bsa) must be ≥2%. * women of childbearing potential will be allowed to participate in the study, and will be required to use at least one form of birth control. exclusion criteria: * use within four weeks from baseline any systemic anti-inflammatory medication, which may influence study outcome, such as systemic corticosteroids. * application or use within two weeks of baseline topical corticosteroid medications or topical anti-inflammatory medication, which may influence study outcome. * presence of a concurrent medical condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments. * introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. * use of anti-histamines while participating in the study will not be permitted unless the subject meets criteria for anti-histamine use on the vas scale. additionally, the subject must remain on a stable dose of anti-histamine throughout the study period. if a patient meets such criteria for anti-histamine use, this will be noted in the subject's chart. * amount of disease involvement that would require \>60 gm of cream in a 1 week period. * subjects with known allergy or sensitivity to topical vanos® cream or components. * pregnant women * women who are breastfeeding

Keywords: eczema itch scratching actigraphy adherence
od-doxy-pnv-covid-19 old drug " doxy " for prevention of new virus " covid-19 "

Conditions: Covid19

Summary: given the urgency of having guidelines for the management of covid-19 in the current epidemic context and the lack of specific pharmacological treatment, military health recommends the launch of a multicenter, randomized, double-blind, interventional clinical trial. the aim of this study is to evaluate the efficacy of a combination of two treatments, low-dose doxcycline (100 mg/day) and zinc (15 mg/day) (dietary supplement) in the primary prevention of covid-19 infection in health care professionals in tunisia compared to two control groups.


Eligibility criteria:
inclusion criteria: * no self-medication with study drugs or antivirals * negative covid19 diagnosis confirmed by pcr and negative elisa antibody assay * no signs of covid19 * having given consent for the study exclusion criteria: participation in other clinical trials aimed at primary prevention of vidoc infection19 * liver failure * known allergy to the study product * pregnancy or breastfeeding * vitamin a and e treatment in progress
remote ischemic conditioning in hsct

Conditions: Hematopoietic Stem Cell Transplantations

Summary: this is a feasibility study at a single site, cincinnati children's hospital medical center. the hypothesis will be tested using a prospective study design. the purpose of the study is to determine tolerability and safety of remote ischemic conditioning in pediatric and adolescent patients undergoing hsct, with the goal of a larger trial of efficacy to follow. the secondary purpose is to determine if remote ischemic conditioning will reduce subclinical cardiotoxicity as measured by markers of myocardial injury and stress in patients undergoing hsct. the study will include multiple blood collections and echocardiograms.


Eligibility criteria:
inclusion criteria: 1. pediatric, adolescent, or young adult patients, 10 years of age or above. 2. able to tolerate upper arm blood pressure inflation. 3. participating in the bmt biorepository (2012-1156). exclusion criteria: 1. systolic blood pressure \>160 mmhg. 2. previous diagnosis of cardiomyopathy (dilated, hypertrophic, restrictive, myocarditis) or congenital heart disease other than bicuspid aortic valve. 3. chronic kidney disease as defined as a pre-transplant gfr \<80 4. central line in both upper extremities. 5. known peripheral vascular disease or vasculitis. 6. platelet count less than 30,000. 7. known clotting disorder or hypercoagulability 8. non-english speaking patients.
exploring the effects of sleep patterns and physical activity on asthma in adolescents with wrist-worn smart devices

Conditions: Asthma

Summary: this is a research study to find associations between asthma symptoms and sleep patterns and physical activity among adolescent patients with persistent asthma. the investigators will collect fitbit® sensor data and survey data from each adolescent enrolled in the study.

investigators from the university of arkansas for medical sciences (pediatrics), the university of arkansas at little rock and the university of florida will work together to conduct a research study to find associations between asthma symptoms, sleep patterns, and physical activity over an 8-week period among adolescent patients with persistent asthma. the goal of this research study is to find new ways for teenagers to manage their asthma. full understanding of the connection and interference of sleep patterns and physical activity with asthma symptoms will be very helpful for teenagers with asthma to better manage their daily routine and asthma care. this research study will use wrist-worn devices (i.e. fitbit® wristbands) to collect participants' sleep and physical activity data.

Eligibility criteria:
inclusion criteria: 1. age ≥ 14 and ≤ 17 years; 2. teen access to a mobile smartphone device with a data plan or a computer with reliable internet connection, compatible with the fitbit® application during the study period; 3. diagnosis of mild, moderate or severe persistent asthma per national heart lung blood institute (nhlbi). exclusion criteria: 1. current smokers and adolescents with significant underlying respiratory disease other than asthma (such as cystic fibrosis) that could potentially interfere with asthma-related outcome measures; 2. prior diagnosis of sleep disorder; 3. patients with significant co-morbid conditions (such as moderate to severe developmental delay) that could interfere with the adolescent's ability to self-monitor asthma; 4. inability to speak or understand english (child or parent).

Keywords: sleep patterns physical activity fitbit
ra effect on cell surface molecules in vivo

Conditions: HIV Infections

Summary: this study will follow a group of healthy male participants for about 18 weeks to see the effect of taking acitretin on their immune cells

retinoids have been shown in in vitro and ex vivo models to have the ability to reverse latency reactivating the hiv reservoir and the potential for selective eradication of hiv-harbouring cells. we feel that acitretin shows significant potential as a potential adjuvant to current art regimens, however, there is a lack of data to demonstrate that treatment with acitretin at normal are able to induce molecular and transcription changes consistent with the above activities. in order to provide a scientific basis for retinoid therapy in hiv infection, a phase i trial of acitretin in human subjects is proposed.

Eligibility criteria:
inclusion criteria: 1. male gender 2. age 18 - 65 3. able to provide informed consent 4. willingness to participate in study treatment and follow-up 5. willingness for serial phlebotomy and storage and future viro-immunological assays exclusion criteria: 1. female gender 2. participants with a known hypersensitivity/allergy to the acitretin. 3. participants who are actively participating in an experimental therapy study or who have received experimental therapy within the last 1 year. 4. participants who are a poor medical risk because of other systemic diseases or active uncontrolled infections including hiv, hepatitis b or c, and tuberculosis 5. participants with impaired glucose tolerance including prediabetes or diabetes mellitus, dyslipidemia, or liver dysfunction 6. previous or current history of mood disorder, psychosis, or suicidality 7. participants currently receiving ongoing treatment with methotrexate, tetracyclines, or other retinoids
a study to evaluate the efficacy of bevacizumab plus irinotecan in recurrent gliomas

Conditions: Glioblastoma; Astrocytoma

Summary: to assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme


Eligibility criteria:
inclusion criteria: * histologically diagnosed recurrent anaplastic astrocytoma or recurrent glioblastoma multiforme * at least 18 years of age * performance status of 0 and 1 on the eastern cooperative oncology group (ecog) criteria * one or more measurable disease * adequate hematologic (neutrophil count \>= 1500/ul, platelets \>= 100,000/ul), hepatic (transaminase =\ = 30ml/min) * expected life time more than at least 2 months * a patients who signed the informed consent prior to the participation in the study exclusion criteria: * a pregnant or lactating patient * a patient of childbearing potential without being tested for pregnancy at baseline or with a positive test. (a premenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.) * a man or woman of childbearing potential without the willingness to use a contraceptive measures during the study * a patient with history of another malignant disease within past 3 years, except curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer * medically uncontrolled serious heart, lung, neurological, psychological, or metabolic disease * uncontrolled serious infection * enrollment in other study within 30 days * hemorrhage on baseline radiologic examination * a patient who refused to sign the informed consent

Keywords: glioblastoma astrocytoma chemotherapy
a study of retatrutide (ly3437943) once weekly in participants who have obesity or overweight and osteoarthritis of the knee

Conditions: Obesity; Overweight; Osteo Arthritis Knee

Summary: the main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (oa) of the knee. the study will lasts about 77 weeks.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) ≥27 kilogram/kg/m² at screening. * have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. * have index knee pain for \>12 weeks prior to screening, and presence of index knee pain for \>15 days over the previous month. * have knee x-ray with moderate radiographic changes (kellgren-lawrence grade 2 or 3) per central reading at screening. * currently meets american college of rheumatology (acr) criteria (clinical and radiological) for oa. exclusion criteria: * have had steroid joint injections within 90 days of screening. * have had other joint injections and procedures within 6 months of screening. * have joint disease other than osteoarthritis. * have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days prior to screening. * have been taking weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * have a prior or planned surgical treatment for obesity. * have diabetes mellitus.